BioSpace News Archive

Recently, the Food and Drug Administration (FDA) issued guidance to expand the availability and capability of non-invasive remote monitoring devices during the COVID-19 pandemic.

Emergent BioSolutions Inc. announced the appointment of Dr. Karen L. Smith, M.D., Ph.D. as chief medical officer with responsibility for leading and further establishing Emergent’s global integrated capability in clinical development, medical affairs, and regulatory affairs.

IMV Inc. (Nasdaq: IMV; TSX: IMV) a clinical-stage biopharmaceutical company, today announced that Company’s management will be participating in Adelaide Capital’s Virtual COVID & Healthcare Mini Conference on April 23, 2020 from 12pm-5pm ET.

A new clinical trial is being announced today that could significantly increase the rate of recovery for COVID-19 patients with underlying health conditions and save lives!

Silk Road Medical, Inc., a company focused on reducing the risk of stroke and its devastating impact, announced it will report financial results for the first quarter 2020 after market close on Thursday, April 30, 2020.

Immunic, Inc. reported that its lead asset, IMU-838, a selective oral DHODH inhibitor, has successfully demonstrated preclinical activity against severe acute respiratory syndrome coronavirus 2.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (“Actinium” or “the Company”) today announced that it intends to offer and sell shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) in an underwritten public offering

Avantor, Inc. announced that its Board of Directors has declared a quarterly cash dividend to holders of its 6.250% Series A Mandatory Convertible Preferred Stock of $0.78 per share at a rate per share of 1.560%, payable on May 15, 2020 to holders of record on May 1, 2020.

Invitae Corporation (NYSE: NVTA), a leading medical genetics company, today announced that it will report its first quarter 2020 financial results on Tuesday, May 5, 2020 and will host a conference call and webcast that day at 4:30 p.m. Eastern / 1:30 p.m.

Vapotherm, Inc. (NYSE: VAPO) (“Vapotherm” or the “Company”), a global medical technology company focused on the development and commercialization of its proprietary Hi-VNI® Technology products that are used to treat patients of all ages suffering from respiratory distress, today announced that it will release financial results for the first quarter of 2020 after the close of trading on Tuesday, May 5, 2020.